The FY2023 (Dec) proxy of Prothena Corp Public LTD names 19 peer companies for pay. Among Prothena Corp Public LTD and these peers, CEO pay was 6th highest of 10 and total shareholder return was 3rd highest of 10.
6th highest of 10in Prothena Corp Public LTD and its pay peers, FY2023 (Dec) by CEO pay:
$3.6M$10.1M
3rd highest of 10in Prothena Corp Public LTD and its pay peers, FY2023 (Dec) by total shareholder return:
$29$1,778
Pay peer group, FY2023 (Dec) proxy
| Arcus Biosciences | ||
| Cytokinetics | ||
| Celldex Therapeutics | ||
| Denali Therapeutics | ||
| Anaptysbio | ||
| Krystal Biotech | ||
| Kura Oncology | ||
| Iovance Biotherapeutics | ||
| Replimune Group | ||
| Alector | Not disclosed | Not disclosed |
| Anavex Life Sciences | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals | Not disclosed | Not disclosed |
| ImmunoGen | Not disclosed | Not disclosed |
| Karuna Therapeutics | Not disclosed | Not disclosed |
| Kodiak Sciences | Not disclosed | Not disclosed |
| Mersana Therapeutics | Not disclosed | Not disclosed |
| NGM Biopharmaceuticals | Not disclosed | Not disclosed |
| Sangamo Therapeutics | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.